Highlights of Recent ACTG Publications

Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis

AIDS, April 2021 Study A5305/17 was a mucosal tissue-focused sub-study of HPTN 069/ACTG 5305.

Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults with HIV

Clinical Infectious Diseases, March 2021 Inflammation is a serious concern among people living with HIV, as it is associated with increased occurrence of other health conditions and death.

Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings

AIDS Care, January 2021 Lower health-related quality of life and lower adherence have been found to be independent predictors of virologic failure among people starting ART in U.

A Phase 1/2 Randomized, Placebo-Controlled Trial of Romidespin in Persons With HIV-1 on Suppressive Antiretroviral Therapy

The Journal of Infectious Diseases, December 2020 This exploratory study sought to determine whether romidepsin could awaken latent (‘sleeping’) HIV from its reservoir as part of an HIV cure “kick and kill strategy.

Physical Function Impairment and Frailty in Middle-Aged People Living With Human Immunodeficiency Virus in the REPRIEVE Trial Ancillary Study PREPARE

The Journal of Infectious Diseases, July 2020 As the lifespan of people living with HIV increases, so too do the number of people aging with HIV (nearly half of people living with HIV in the United States are now at least 50 years old).

Association of Male Sex and Obesity With Residual Plasma Human Immunodeficiency Virus 1 Viremia in Persons on Long-Term Antiretroviral Therapy

The Journal of Infectious Diseases, June 2020 Persistence of detectable HIV despite perfect ART adherence can be worrisome, because reaching undetectable is a huge goal for many people living with HIV.

Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy

JAIDS, June 2020 In resource-limited settings, there are fewer regimens available to people living with HIV compared to individuals in resource-rich countries.

Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral Therapy

JAIDS, June 2020 In resource-limited settings, there are fewer regimens available to people living with HIV compared to individuals in resource-rich countries.

Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy

AIDS Research and Human Retroviruses, April 2020 The last few years have witnessed increased interest in treating HIV with two instead of three active drugs.